Helically constrained stapled peptides recognized amyloid-β fibril surfaces with submicromolar affinity (~0.75 μM) and effectively inhibited surface-mediated toxic oligomer formation.
~0.75 μMbinding affinity of the best stapled peptide inhibitor for amyloid-β fibril surfaces
What the researchers found
Stapled helical peptides recognized the K16-E22 region of Aβ40 fibril surfaces and inhibited surface-mediated oligomerization. The best candidate achieved ~0.75 μM binding affinity through hydrophobic staple-fibril surface interactions.
Why it matters
Most Alzheimer's drug approaches target soluble amyloid or prevent aggregation. Targeting the fibril surface — the actual platform that generates toxic oligomers — is a novel strategy that could complement existing approaches.
The numbers in context
Helical peptide bound Aβ40 fibril surface K16-E22 region with micromolar affinity; blocked toxic oligomer formation.
How the study worked
Peptide synthesis with in-tether chiral center-induced helical stabilization. Binding affinity measurements. Extensive computational sampling revealing two distinct binding modes. Oligomerization inhibition assays.
Who was studied
Amyloid-beta fibril preparations in vitro
What this study cannot tell us
In vitro study — no cellular or animal model testing. The relationship between fibril surface-mediated oligomerization and Alzheimer's pathology in vivo needs validation. Peptide drug delivery to the brain remains a major challenge.
How to read the evidence
In vitro proof-of-concept with computational validation. Novel target approach but early-stage without cellular or animal testing.
When this study was published
Published in 2020. Stapled peptide approaches for neurodegenerative diseases continue to be explored.
The bigger picture
The repeated failures of anti-amyloid drugs in Alzheimer's trials have pushed researchers to explore alternative targets. Fibril surfaces as oligomer generators represent a compelling new target, and stapled peptides provide the molecular tools to hit them.
Questions still open
- Can these stapled peptides cross the blood-brain barrier to reach amyloid deposits?
- Would inhibiting fibril surface-mediated oligomerization reduce neurotoxicity in animal models?
- Could this approach be applied to other amyloid diseases like Parkinson's or type 2 diabetes?
Common questions
What are stapled peptides?
Why target fibril surfaces instead of amyloid itself?
Read the original research
Targeting the Amyloid-β Fibril Surface with a Constrained Helical Peptide Inhibitor.
Biochemistry, 59(3), 290-296
Citation
Yang, Fadeng; Zhang, Wan; Jiang, Yixiang; Yin, Feng; Han, Wei; Li, Zigang. (2020). Targeting the Amyloid-β Fibril Surface with a Constrained Helical Peptide Inhibitor.. Biochemistry, 59(3), 290-296. https://doi.org/10.1021/acs.biochem.9b00800